🇺🇸 FDA
Pipeline program

Mivelsiran, Placebo

ALN-APP-002

Phase 2 small_molecule active

Quick answer

Mivelsiran, Placebo for Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain is a Phase 2 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Alnylam Netherlands B.V.
Indication
Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials